Navigating Access & Policy Barriers for the Next Generation of Cell & Gene Therapies

• Addressing access obstacles and new considerations in emerging indications to expand CAR‑T cell therapy and gene therapy delivery beyond oncology and smaller indications
• Policy challenges and opportunities to broaden treatment reach across the US outside major academic centres and improving patient access pathways
• Identifying key areas of reimbursement and access policy shaping that will enable future patients to receive innovative therapies

Speakers:

Jodie Wehling

vp market access

Mesoblast Ltd.

Arielle Gurwitch

Senior Director, US Public Policy 

Eli Lilly & Co.